DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteogenesis imperfecta, type 19 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteogenesis imperfecta, type 19 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteogenesis imperfecta, type 19 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1981 review of published articles on osteogenesis imperfecta found that seventy percent of them claimed beneficial results for twenty different agents, yet the same review stated that no form of treatment had been accepted as effective. It concluded that at that time no agent was available of any value to a practitioner treating a patient with osteogenesis imperfecta, and advised maintaining a high degree of scepticism toward positive results regardless of source.
A 2013 article on what is new in osteogenesis imperfecta discussed the pathophysiology of the condition, noting that while it was historically considered a collagen-related condition due to mutations in genes encoding the alpha chains of collagen type I, mutations in various noncollagenous genes had more recently been discovered to cause some rare recessive forms. This article did not report any clinical trial results or treatment outcomes.
A 2016 study from Spain examined the educational inclusion experience of a single university student with osteogenesis imperfecta in a physical education course. It reported stigmatisation of the student at both personal and academic levels, and described the teacher's adaptations to ensure inclusion. No drug treatment or medical outcome was studied.
What is still missing for osteogenesis imperfecta type 19 specifically is any clinical trial data, any identified drug candidate, any patient stratification, and any funding directed toward a treatment for this particular genetic subtype. The literature provides no evidence of efficacy for any agent in this form of the disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Orthopaedics and Related Research · 1981 · 40 citations
Systemic Treatment of Osteogenesis Imperfecta
AbstractSeventy percent of published articles on the medical treatment of osteogenesis imperfecta have claimed beneficial results for 20 different agents. This observation conflicts with current practice since no form of treatment has been accepted as effective in dealing with the disease. A few medications or combinations of medications hold some promise, but adequate documentation must be availble before they can be accurately assessed. It is essential that the practitioner maintain a high degree of skepticism toward positive results of treatment regardless of the source. At the present time, no agent is available which will be of any value to the practitioner who has a patient with osteogenesis imperfecta.
Estudios pedagógicos · 2016 · 10 citations · open access
Osteogénesis imperfecta y educación física: Un caso inédito de inclusión educativa
AbstractEl objetivo principal de este trabajo es indagar en la experiencia de inclusión educativa vivida por una alumna con osteogénesis imperfecta y por sus compañeras en una asignatura universitaria con contenidos relacionados con la educación física. La recogida de datos sobre la experiencia se realizó a lo largo de un cuatrimestre a partir de conversaciones informales con el profesor, entrevistas en profundidad y semi-estructuradas, y un cuestionario de respuesta abierta. El estudio revela la estigmatización sufrida por la alumna, tanto a nivel personal como académico (sobre todo en las clases de educación física) y el desconocimiento e inseguridad que manifiesta tener el futuro profesorado sobre esta enfermedad y cómo realizar un tratamiento inclusivo en sus clases. Asimismo, se describen las adaptaciones realizadas por el profesor de la asignatura con el fin de garantizar y ejemplificar la inclusión de una alumna con osteogénesis imperfecta en las clases de educación física.
AbstractThis article discusses the pathophysiology of osteogenesis imperfecta (OI), in particular in relation to some rare, recessive forms of the condition. Although historically considered a collagen-related condition, predominantly due to mutations in genes that encode the alpha chains of collagen type I, mutations in various noncollagenous genes have also more recently been discovered to cause some forms of OI.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
